Research paper
Metabolite complex formation of orphenadrine with cytochrome P450: Involvement of CYP2C11 and CYP3A isozymes

https://doi.org/10.1016/0006-2952(96)00140-2Get rights and content

Abstract

Expression and inhibition of cytochrome P450 (CYP) isozymes capable of forming an orphenadrine metabolite complex were studied in microsomes of untreated and inducer-treated male and female rats. High levels of complex-forming isozymes were found in microsomes of untreated male as compared to female rats. Treatment of male rats with several P450 inducers did not considerably increase the extent of in vitro complex formation. In female rats, however, phenobarbital or dexamethasone treatments led to pronounced induction. The isozyme specifity of complex formation was investigated by several approaches including: 1. inhibition by orphenadrine of isozyme-specific P450 activities, such as hydroxylation of testosterone, O-dealkylation of pentoxy- and ethoxyresorufin and complex formation with triacetyloleandomycin (TAO), 2. inhibition of orphenadrine complex formation by metyrapone, TAO, and cimetidine, and 3. correlation of complex levels with immunochemically, enzymatically, or spectroscopically determined amounts of P450 isozymes. Our data suggest that CYP2C11, a CYP3A isozyme and an unidentified P450 species are involved in complex formation with orphenadrine, but exclude the involvement of CYP1A1/2 and CYP2B1/2. The capability of CYP2C11 to form a metabolite complex with orphenadrine is strongly suggested for the following reasons: 1. Efficient inhibition of testosterone 2α- and 16α-hydroxylation by complex formation with orphenadrine in microsomes of untreated male rats, 2. high expression of orphenadrine-complexing isozymes in untreated male compared to female rats, 3. specific inhibition of in vitro complex formation by cimetidine, 4. suppression of complex-forming isozymes by 3-methylcholanthrene and β-naphthoflavone, and 5. concomitant induction of complex-forming isozymes, immunodetectable CYP2C11, and testosterone 2α-hydroxylase by stanozolol. That at least one, but not all, CYP3A isozymes is involved in complex formation is concluded from inhibition experiments with TAO that show that orphenadrine complexation can be significantly inhibited in microsomes of dexamethasone-treated, but not in microsomes of untreated rats. Furthermore, complex formation with TAO is not inhibited by orphenadrine in microsomes of phenobarbital (PB)-treated rats. In PB-treated female rats, a further unidentified complex-forming isozyme can be detected that is not inhibited by complex formation with TAO.

References (59)

  • FP Guengerich

    Separation and purification of multiple forms of microsomal cytochrome P-450. Partial characterization of three apparently homogeneous cytochromes P-450 prepared from livers of phenobarbital and 3-methylcholanthrene-treated rats

    J Biol Chem

    (1977)
  • MD Burke et al.

    Ethoxy-, pentoxy and benzyloxyphenoxa-zones and homologues: a series of substrates to distinguish between different induced cytochromes P-450

    Biochem Pharmacol

    (1985)
  • OH Lowry et al.

    Protein measurement with the Folin phenol reagent

    J Biol Chem

    (1951)
  • T Omura et al.

    The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature

    J Biol Chem

    (1964)
  • DE Ryan et al.

    Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls, phenobarbital, and 3-methylcholanthrene

    J Biol Chem

    (1979)
  • DJ Winzor et al.

    The nature of microsomal monooxygenase inhibition by cimetidine

    Biochem Pharmacol

    (1986)
  • JC Jensen et al.

    Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450

    Biochem Pharmacol

    (1985)
  • PE Thomas et al.

    Induction of two immunochemically related rat liver cytochrome P-450 isozymes, cytochrome P-450c and P-450d, by structurally diverse xenobiotics

    J Biol Chem

    (1983)
  • PE Thomas et al.

    Preparation of monospecific antibodies against two forms of rat liver cytochrome P-450 and quantitation of these antigens in microsomes

    Arch Biochem Biophys

    (1979)
  • SS Park et al.

    Monoclonal antibodies to rat liver cytochrome P-450 2c/RLM5 that regiospecifically inhibit steroid metabolism

    Biochem Pharmacol

    (1989)
  • DJ Waxman et al.

    Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver

    J Biol. Chem

    (1983)
  • D Strotkamp et al.

    A novel CYP3 gene from female rats

    Biochim Biophys Acta

    (1995)
  • S Kirita et al.

    cDNA cloning and characterization of a novel member of steroid-induced cytochrome P450 3A in rats

    Arch Biochem Biophys

    (1993)
  • FP Guengerich et al.

    Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism

    J Biol Chem

    (1986)
  • CF Neville et al.

    Characterization of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats

    Biochem Pharmacol

    (1993)
  • JR Halpert et al.

    Selective inhibitors of cytochrome P450

    Toxicol Appl Pharmacol

    (1994)
  • R Kato et al.

    Sex-specific cytochrome P450 as a cause of sex-related and species-related differences in drug toxicity

    Toxicol Lett

    (1992)
  • E Eliasson et al.

    Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation

  • B Testa

    Mechanisms of inhibition of xenobiotic-metabolizing enzymes

    Xenobiotica

    (1990)
  • Cited by (0)

    Part of the results were presented at the International Congress on Cytochrome P450: Biochemistry, Biophysics and Molecular Biology, Lisbon, 1993.

    View full text